Previously, he was the chief medical officer at PolyMedix Inc., where he worked on brilacidin, the first in a new class of antibiotics known as defensin-mimetics, and thereafter he continued his work as a consultant to Cellceutix, before joining Cellceutix as CMO. Jorgensen has a special interest in the development of single-dose and short- course antibiotics, particularly those that can reduce the burden of antimicrobial resistance.